Actinium Pharmaceuticals (ATNM) Competitors $1.50 -0.15 (-9.09%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ATNM vs. NBTX, TSVT, HRTX, CRBU, NKTX, DRUG, LFVN, SCPH, TIL, and MDWDShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Nanobiotix (NBTX), 2seventy bio (TSVT), Heron Therapeutics (HRTX), Caribou Biosciences (CRBU), Nkarta (NKTX), Bright Minds Biosciences (DRUG), LifeVantage (LFVN), scPharmaceuticals (SCPH), Instil Bio (TIL), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Nanobiotix 2seventy bio Heron Therapeutics Caribou Biosciences Nkarta Bright Minds Biosciences LifeVantage scPharmaceuticals Instil Bio MediWound Nanobiotix (NASDAQ:NBTX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation. Does the MarketBeat Community believe in NBTX or ATNM? Nanobiotix received 7 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 64.71% of users gave Nanobiotix an outperform vote while only 33.33% of users gave Actinium Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNanobiotixOutperform Votes1164.71% Underperform Votes635.29% Actinium PharmaceuticalsOutperform Votes433.33% Underperform Votes866.67% Do analysts recommend NBTX or ATNM? Nanobiotix presently has a consensus target price of $11.50, suggesting a potential upside of 192.62%. Actinium Pharmaceuticals has a consensus target price of $11.40, suggesting a potential upside of 660.00%. Given Actinium Pharmaceuticals' higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is NBTX or ATNM more profitable? Nanobiotix's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NanobiotixN/A N/A N/A Actinium Pharmaceuticals N/A -98.93%-47.27% Does the media prefer NBTX or ATNM? In the previous week, Nanobiotix and Nanobiotix both had 6 articles in the media. Nanobiotix's average media sentiment score of 1.03 beat Actinium Pharmaceuticals' score of 0.60 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Actinium Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, NBTX or ATNM? Nanobiotix has higher revenue and earnings than Actinium Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanobiotix$39.18M4.73-$42.97MN/AN/AActinium Pharmaceuticals$80K585.00-$48.82M-$1.39-1.08 Which has more risk and volatility, NBTX or ATNM? Nanobiotix has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Do institutionals and insiders believe in NBTX or ATNM? 38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryNanobiotix beats Actinium Pharmaceuticals on 10 of the 13 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$46.79M$6.52B$5.15B$19.84BDividend YieldN/A8.16%5.18%3.51%P/E Ratio-1.084.8866.3735.16Price / Sales585.00376.691,276.8417.75Price / CashN/A51.2039.7021.33Price / Book1.159.686.474.64Net Income-$48.82M$154.43M$119.73M$982.94M7 Day Performance-21.88%-9.46%-5.13%-2.12%1 Month Performance-12.79%-7.27%-2.71%-0.39%1 Year PerformanceN/A28.13%31.08%23.34% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals1.6219 of 5 stars$1.50-9.1%$11.40+660.0%N/A$46.79M$80,000.00-1.0849Analyst ForecastNews CoverageHigh Trading VolumeNBTXNanobiotix2.3844 of 5 stars$3.93-3.0%$11.50+192.6%-34.5%$185.23M$39.18M0.00100News CoveragePositive NewsGap DownTSVT2seventy bio2.4942 of 5 stars$3.52-10.2%$9.00+155.7%+66.4%$181.59M$100.39M-1.89440News CoverageHRTXHeron Therapeutics4.0402 of 5 stars$1.19-4.0%$5.67+376.2%+29.8%$180.99M$127.04M-6.61300Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageCRBUCaribou Biosciences2.9898 of 5 stars$1.99-4.8%$11.25+465.3%-57.9%$180.20M$34.48M-1.21100Analyst ForecastShort Interest ↓News CoverageNKTXNkarta2.3687 of 5 stars$2.53-6.3%$16.50+552.2%+7.2%$178.54MN/A-1.35140DRUGBright Minds Biosciences2.4096 of 5 stars$39.61-7.8%N/A+2,994.5%$175.62MN/A-58.25N/AShort Interest ↓Positive NewsGap DownLFVNLifeVantage3.0507 of 5 stars$13.83+0.1%N/A+182.8%$173.22M$200.16M43.22260SCPHscPharmaceuticals4.022 of 5 stars$3.46+3.0%$15.00+333.5%-31.1%$173.14M$13.59M-1.8230Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeTILInstil Bio2.8705 of 5 stars$26.50-10.0%$145.00+447.2%+294.1%$172.94MN/A-2.2949Analyst ForecastNews CoverageGap DownMDWDMediWound2.0214 of 5 stars$16.00-2.3%$29.00+81.3%+93.2%$172.58M$18.69M-7.4180Upcoming EarningsPositive News Related Companies and Tools Related Companies Nanobiotix Alternatives 2seventy bio Alternatives Heron Therapeutics Alternatives Caribou Biosciences Alternatives Nkarta Alternatives Bright Minds Biosciences Alternatives LifeVantage Alternatives scPharmaceuticals Alternatives Instil Bio Alternatives MediWound Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ATNM) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
